1. The attenuated strain of Salmonella typhi mutant, comprising at least one copy of a recombinant DNA molecule comprising an expression cassette encoding a protein receptors VEGF, in particular, receptor protein VEGF, selected from the group consisting of VEGFR-2 and its human homolog, which degree of homology is at least about 80%, especially where human VEGFR-2 has the amino acid sequence as shown in SEQ ID NO: 1, for use as vaktsiny.2. DNA vaccine comprising an attenuated Salmonella typhi mutant strain according to Claim. 1, wherein the attenuated strain of Salmonella typhi mutant is Salmonella typhi Ty21a, and in which the expression cassette is a eukaryotic expression cassette, for use in immunotherapy of malignant opuholey.3. . The DNA vaccine of claim 2, wherein the DNA vaccine comprises an attenuated strain of Salmonella typhi Ty21a, transformed with a plasmid which comprises DNA encoding a protein VEGFR-2 with SEQ ID NO: 1, for use in anti-angiogenic immunotherapy of malignant opuholey.4. The DNA vaccine of claim. 3, where the plasmid is pVAX10.VR2-1 size 7580 bp, as shown in FIG. 2, and has the sequence as shown in SEQ ID NO: 3, and DNA vaccine has the name VXM01.5. The DNA vaccine of claim. 2, wherein the cancer is pancreatic cancer zhelezy.6. The DNA vaccine of claim. 5, wherein said pancreatic cancer is at stage IV or a locally advanced pancreatic zhelezy.7. The DNA vaccine of claim. 2, wherein the cancer comprises metastazy.8. The DNA vaccine of claim. 2, where the treatment is carried out accompanied by chemotherapy and / or radiation terapii.9. DNA vaccine according to claim. 8, where the chemotherapeutic agent is1. Аттенуированный мутантный штамм сальмонеллы тифи, содержащий, по меньшей мере, одну копию рекомбинантной молекулы ДНК, содержащую экспрессирующую кассету, кодирующую рецепторы белка VEGF, в частности, рецепторный белок VEGF, выбранный из группы, состоящей из VEGFR-2 человека и его гомолога, степень гомологии которых составляет, по меньше
